Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

Benjamin Garmezy,Tian Zhang,Andrew Leonard Laccetti,Minas P. Economides,Amishi Yogesh Shah,Nizar M. Tannir,Eric Jonasch,Pavlos Msaouel,Amado J. Zurita,Paul G. Corn,Aradhana M. Venkatesan,Landon Carter Brown,Chester Kao,Emily Noelle Kinsey,Michael R. Harrison,Andrew J. Armstrong,Daniel J. George,Matthew T. Campbell

Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

2020

Benjamin Garmezy
Tian Zhang
Andrew Leonard Laccetti
Minas P. Economides
Amishi Yogesh Shah
Nizar M. Tannir
Eric Jonasch
Pavlos Msaouel
Amado J. Zurita
Paul G. Corn
Aradhana M. Venkatesan
Landon Carter Brown
Chester Kao
Emily Noelle Kinsey
Michael R. Harrison
Andrew J. Armstrong
Daniel J. George
Matthew T. Campbell

e17090Background: Two immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combinations are FDA-approved for patients (pts) with metastatic renal cell carcinoma (mRCC). Here we present a multicen...

Keywords:

Tyrosine kinase
Renal cell carcinoma
in patient
Nivolumab
Combination therapy
Pathology
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations